Pasireotide treatment significantly reduces tumor volume in patients with Cushing ’s disease: results from a Phase 3 study

ConclusionsMeasurable decreases in pituitary tumor volume were observed in a large proportion of patients with CD and measurable tumor volume who were enrolled in the trial and treated with subcutaneous pasireotide; this decrease was not correlated with UFC control.ClinicalTrials.gov identifierNCT00434148.
Source: Pituitary - Category: Endocrinology Source Type: research